# OnCo record lung-net (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/lung-net/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "lung-net" ;
  schema:name "Lung neuroendocrine tumours (typical and atypical carcinoid)"@en ;
  schema:alternateName "Bronchial carcinoid"@en, "Pulmonary carcinoid"@en, "Typical carcinoid"@en, "Atypical carcinoid"@en, "Lung NET"@en, "Bronchopulmonary neuroendocrine tumour"@en ;
  schema:description "Lung neuroendocrine tumours, called typical and atypical carcinoids, are slow-growing tumours of the airways that are usually cured by surgery. When they spread, everolimus is the one drug tested in a randomised trial for this site, cabozantinib was approved in 2025, and somatostatin analogues and lutetium radioligand therapy are borrowed from gut tumours."@en ;
  schema:url <https://onco.cc/cancers/lung-net/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Neuroendocrine_tumor> ;
  schema:citation <https://doi.org/10.1016/S0140-6736(15)00817-X>, <https://doi.org/10.1056/NEJMoa2403991>, <https://en.wikipedia.org/wiki/Neuroendocrine_tumor> ;
  onco:tag "subtype-page", "endocrine", "lung" ;
  onco:technologies <https://onco.cc/technologies/sstr-pet/>, <https://onco.cc/technologies/prrt/>, <https://onco.cc/terms/bronchoscopy/>, <https://onco.cc/technologies/ct/> ;
  onco:targets <https://onco.cc/targets/sstr2/>, <https://onco.cc/targets/mtor/> ;
  onco:drugs <https://onco.cc/drugs/everolimus/>, <https://onco.cc/drugs/cabozantinib/>, <https://onco.cc/drugs/octreotide-lanreotide/>, <https://onco.cc/drugs/lutathera/>, <https://onco.cc/drugs/ga68-dotatate/> ;
  onco:terms <https://onco.cc/terms/lobectomy/>, <https://onco.cc/terms/net-grade-ki67/>, <https://onco.cc/terms/carcinoid-syndrome/>, <https://onco.cc/terms/chromogranin-a/> ;
  onco:trials <https://onco.cc/trials/radiant-3-4/>, <https://onco.cc/trials/cabinet/> ;
  onco:pipeline <https://onco.cc/trials/cabinet/>, <https://onco.cc/trials/nct06943755/>, <https://onco.cc/technologies/prrt/>, <https://onco.cc/technologies/sstr-pet/> ;
  onco:standardOfCare <https://onco.cc/terms/bronchoscopy/>, <https://onco.cc/technologies/ct/>, <https://onco.cc/technologies/sstr-pet/>, <https://onco.cc/drugs/ga68-dotatate/>, <https://onco.cc/terms/net-grade-ki67/>, <https://onco.cc/terms/lobectomy/>, <https://onco.cc/technologies/robotic-surgery/>, <https://onco.cc/drugs/octreotide-lanreotide/>, <https://onco.cc/trials/clarinet/>, <https://onco.cc/drugs/everolimus/>, <https://onco.cc/trials/radiant-3-4/>, <https://onco.cc/drugs/cabozantinib/>, <https://onco.cc/trials/cabinet/>, <https://onco.cc/drugs/lutathera/>, <https://onco.cc/technologies/prrt/>, <https://onco.cc/drugs/capecitabine-temozolomide/>, <https://onco.cc/drugs/octreotide-lanreotide/>, <https://onco.cc/terms/carcinoid-syndrome/> .